Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5443_Библиотеки_им_академика_М_И_Перельмана
.pdf
11.13 Future prospects
Molecular simulations of excipient compatibility is a fast developing topic with prom-
ising future applications. To get a fuller picture of how excip ients interact with one
another, multi-scale simulations can integrate several simulation levels, from QM to
coarse-grained simulations. The compatibility of excipients can be predicted with the
use of machine learning algorithms. To learn to recognize patterns and make compat-
ibility predictions, these models can be fed enormous amounts of information from
experiments and simulations. High-throughput molecular simulation screening for ex-
cipient compatibility can reveal promising excipient combinations for follow-up ex-
periments. Excipient–excipient compatibility research using molecular simulations
shows promise. Molecular simulations are becoming increasingly useful in the pro-
cess of creating new pharmaceutical formulations as computing power and simula-
tion techniques increase.
11.14 Conclusions
The fundamental objec tive of excipient compatibility studies is to determine which
components of the dosage form are safe to use in conjunction with the medicine. Care-
fully planned experiments not only reveal the drug’s stability profile, but also reveal
degradation products and their underlying mechanisms. The potential for developing
superior drug delivery systems is enhanced by the availability of novel synthetic or
naturally functional materials. Methods for calculating and predicting solubility used
computational modeling, with a focus on molecular simulation. We have made an ef-
fort to illustrate how simulations might be used to direct and even anticipate experi-
mental results. As computing power rises, a wider variety of complicated systems
may be investigated.
References
[1] Duarte Ramos Matos, G., et al. Approaches for calculating solvation free energies and enthalpies
demonstrated with an update of the FreeSolv database. Journal of Chemical and Engineering Data,
2017, 62, 1559–1569.
[2] Bannan, C. C., Calabró, G., Kyu, D. Y., & Mobley, D. L. Calculating partition coefficients of small
molecules in octanol/water and cyclohexane/water. Journal of Chemical Theory and Computation,
2016, 12, 4015–4024.
[3] Bergström, C. A. S., & Larsson, P. Computational prediction of drug solubility in water-based
systems: Qualitative and quantitative approaches used in the current drug discovery and
development setting. International Journal of Pharmaceutics, 2018, 540, 185–193.
[4] Liu, S., et al. using md simulations to calculate how solvents modulate solubility. Journal of Chemical
Theory and Computation, 2016, 12, 1930–1941.
11 Applications and molecular simulation strategies 263
https://t.me/med1917
[5] Li, L., Totton, T., & Frenkel, D. Computational methodology for solubility prediction: Application to
the sparingly soluble solutes. Journal of Chemical Physics, 2017, 146, 214110.
[6] Shadrack Jabes, B., Krekeler, C., Klein, R., & Delle Site, L. Probing spatial locality in ionic liquids with
the grand canonical adaptive resolution molecular dynamics technique. Journal of Chemical Physics,
2018, 148, 193804.
[7] Callaway, C. P., et al. Molecular modeling approach to determine the flory‐huggins interaction
parameter for polymer miscibility analysis. ChemPhysChem, 19, 2018.
[8] Oddone, I., Barresi, A. A., & Pisano, R. Influence of controlled ice nucleation on the freeze-drying of
pharmaceutical products: The secondary drying step. International Journal of Pharmaceutics, 2017,
524(1–2), 134–140.
[9] Hauptmann, A., Podgorsek, K., Kuzman, D., Srcic, S., Hoelzl, G., & Loerting, T. Impact of buffer,
protein concentration and sucrose addition on the aggregation and particle formation during
freezing and thawing. Pharmaceutical Research (N Y), 2018, 35(5), 101.
[10] Zhang, A., Singh, S. K., Shirts, M. R., Kumar, S., & Fernandez, E. J. Distinct aggregation mechanisms
of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange.
Pharmaceutical Research , 2012, 29(1), 236–250.
[11] Kolhe, P., & Badkar, A. Protein and solute distribution in drug substance containers during frozen
storage and post-thawing: A tool to understand and define freezing-thawing parameters in
biotechnology process development. Biotechnology Progress, 2011, 27(2), 494–504.
[12] Webb, S. D., Webb, J. N., Hughes, T. G., Sesin, D. F., & Kincaid, A. C. Freezing bulk-scale
biopharmaceuticals using common techniques: And the magnitude of freeze concentration.
Biopharm (Jilove), 2002, 15(5), 22–34.
[13] Lashmar, U. T., Vanderburgh, M., & Little, S. J. Bulk freeze-thawing of macromolecules: Effects of
cryoconcentration on their formulation and stability. Bioprocess International, 2007, 5(6), 44.
[14] Leach, A. R. Molecular Modelling: Principles and Applications. 2001, 2nd ed., Pearson Education:
Harlow, UK.
[15] Van Gunsteren, W. F., & Berendsen, H. J. C. Computer simulation of molecular dynamics:
Methodology, applications, and perspectives in Chemistry. Angewandte Chemie International
Edition in English, 1990, 29, 992–1023.
[16] Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., &
Bourne, P. E. The Protein Data Bank. Nucleic Acids Research, 2000, 28, 235–242.
[17] Kuhlman, B., & Bradley, P. Advances in protein structure prediction and design. Nature Reviews
Molecular Cell Biology, 2019, 20, 681–697.
[18] Monticelli, L., & Tieleman, D. P. Force fields for classical molecular dynamics. Molecular Biology and
Methods, 2013, 924, 197–213.
[19] Lyubartsev, A. P., & Rabinovich, A. L. Force field development for lipid membrane simulations.
Biochimica Biophysica (BBA)-Biomembranes, 2016, 1858, 2483–2497.
[20] Lin, F. Y., & MacKerell, A. D., Jr Force fields for small molecules. Methods in Molecular Biology, 2019,
2022, 21–54.
[21] Hubbard, R. E. Molecular graphics and modeling: Tools of the trade. In: Cohen, N. C. (ed) Guidebook
on Molecular Modeling in Drug Design. 1996 (pp. 19– 54). Academic Press: New York, NY, USA.
[22] Hess, B., Kutzner, C., Van der Spoel, D., & Lindahl, E. GROMACS 4: Algorithms for highly efficient,
load-balanced, and scalable molecular simulation. Journal of Chemical Theory and Computation,
2008, 4, 435–447.
[23] Salomon-Ferrer, R., Case, D. A., & Walker, R. C. An overview of the Amber biomolecular simulation
package. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2013, 3, 198–210.
[24] Phillips, J. C., Hardy, D. J., Maia, J. D. C., Stone, J. E., Ribeiro, J. V., Bernardi, R. C., Buch, R., Fiorin, G.,
Hénin, J., Jiang, W., et al. Scalable molecular dynamics on CPU and GPU architectures with NAMD.
Journal of Chemical Physics, 2020, 153, 044130.
264 Aditya Sharma et al.
https://t.me/med1917
[25] Brooks, B. R., Brooks, C. L., III, Mackerell, A. D., Jr, Nilsson, L., Petrella, R. J., Roux, B., Won, Y.,
Archontis, G., Bartels, C., Boresch, S., et al. CHARMM: The biomolecular simulation program. Journal
of Computational Chemistry, 2009, 30, 1545–1614.
[26] Abdel-Halim, H., Traini, D., Hibbs, D., Gaisford, S., & Young, P. Modelling of molecular phase
transitions in pharmaceutical inhalation compounds: An in silico approach. European Journal of
Pharmaceutics and Biopharmaceutics, 2011 May, 78(1), 83–89.
[27] Adnan, A., Lam, R., Chen, H., Lee, J., Schaffer, D. J., Barnard, A. S., . . . Liu, W. K. Atomistic simulation
and measurement of pH dependent cancer therapeutic interactions with nanodiamond carrier.
Molecular Pharmaceutics, 2011, 8, 368–374.
[28] Ajay,, & Murcko, M. A. Computational methods to predict binding free energy in ligand-receptor
complexes. Journal of Medicinal Chemistry, 1995 Dec, 38(26), 4953–4967.
[29] Allen, M. P., & Tildesley, D. J. Computer Simulation of Liquids. 1989, Oxford University Press:
New York, NY, Alper, H. E., & Stouch, T. R. (1995 Apr). Orientation and diffusion of a drug analog in
biomembranes: Molecular dynamics simulations. The Journal of Physical Chemistry, 99(15),
5724–5731.
[30] Arnarez, C., Uusitalo, J. J., Masman, M. F., Ingólfsson, H. I., de Jong, D. H., Melo, M. N., . . . Marrink,
S. J. Dry Martini, a coarse-grained force field for lipid membrane simulations with implicit solvent.
Journal of Chemical Theory and Computation, 2015 Jan 13, 11(1), 260–275.
[31] Baginski, M., Resat, H., & McCammon, J. A. Molecular properties of amphotericin B membrane
channel: A molecular dynamics simulation. Molecular Pharmacology, 1997 Oct, 52(4), 560–570.
[32] Barducci, A., Bussi, G., & Parrinello, M. Well-tempered Metadynamics: A smoothly converging and
tunable free-energy method. Physical Review Letters, 2008 Jan 18, 100(2), 20603.
[33] Barton, A. F. M. CRC Handbook of Solubility Parameters and Other Cohesion Parameters. 1991, 2nd
ed., CRC press: Boca Raton, FL, Bemporad, D., Luttmann, C., & Essex, J. W. (2005). Behaviour of small
solutes and large drugs in a lipid bilayer from computer simulations. Biochimica et Biophysica Acta
(BBA) – Biomembranes, 1718(1–2), 1–21.
[34] Bernini, M. C., Fairen-Jimenez, D., Pasinetti, M., Ramirez-Pastor, A. J., & Snurr, R. Q. Screening of
bio-compatible metal–organic frameworks as potential drug carriers using Monte Carlo simulations.
Journal of Materials Chemistry B, 2014, 2(7), 766–774.
[35] Beveridge, D. L., & DiCapua, F. M. Free energy via molecular simulation: Applications to chemical
and biomolecular systems. Annual Review of Biophysics and Biophysical Chemistry, 1989 Jun 28,
18(1), 431–492.
[36] Birru, W. A., Warren, D. B., Han, S., Benameur, H., Porter, C. J. H., Pouton, C. W., & Chalmers,
D. K. Computational models of the gastrointestinal environment. 2. Phase behavior and drug
solubilization capacity of a type I lipid-based drug formulation after digestion. Molecular
Pharmaceutics, 2017, 14(3), 580–592.
[37] Boggara, M. B., & Krishnamoorti, R. Partitioning of nonsteroidal anti-inflammatory drugs in lipid
membranes: A molecular dynamics simulation study. Biophysical Journal, 2010, 98(4), 586–595.
[38] Carpenter, T. S., Kirshner, D. A., Lau, E. Y., Wong, S. E., Nilmeier, J. P., & Lightstone, F. C. A method to
predict blood-brain barrier permeability of drug-like compounds using molecular dynamics
simulations. Biophysical Journal, 2014 Aug, 107(3), 630– 641.
[39] Chen, T., D’Addio, S. M., Kennedy, M. T., Swietlow, A., Kevrekidis, I. G., Panagiotopoulos, A. Z., &
Prud’homme, R. K. Protected peptide nanoparticles: Experiments and Brownian dynamics
simulations of the energetics of assembly. Nano Letters, 2009, 9(6), 2218– 2222.
[40] Cherkasov, A., Muratov, E. N., Fourches, D., Varnek, A., Baskin, I. I., Cronin, M., . . . Tropsha, A. QSAR
modeling: Where have you been? Where are you going to?. Journal of Medicinal Chemistry, 2014
Jun 26, 57(12), 4977–5010.
[41] Cho, K., & Joannopoulos, J. D. Ergodicity and dynamical properties of constant-temperature
molecular dynamics. Physical Review A, 1992 May 1, 45(10), 7089–7097.
11 Applications and molecular simulation strategies 265
https://t.me/med1917
[42] De Vivo, M., Masetti, M., Bottegoni, G., & Cavalli, A. Role of molecular dynamics and related methods
in drug discovery. Journal of Medicinal Chemistry, 2016 May 12, 59(9), 4035–4061.
[43] Dror, R. O., Dirks, R. M., Grossman, J. P., Xu, H., & Shaw, D. E. Biomolecular simulation: A
computational microscope for molecular biology. Annual Review of Biophysics, 2012 Jun 9, 41(1),
429–452.
[44] van de Waterbeemd, H., Smith, D. A., Beaumont, K., & Walker, D. K. Property-based design:
Optimization of drug absorption and pharmacokinetics. Journal of Medicinal Chemistry, 2001, 44,
1313YY1333.
[45] Waterbeemdvan de, H., Smith, D. A., & Jones, B. C. Lipophilicity in PK design: Methyl, ethyl, futile.
Journal of Computer-Aided Molecular Design, 2001, 15, 273YY286.
[46] Avdeef, A. Absorption and Drug Development. 2003, (pp. 116YY246). Wiley: New York.
[47] Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. Journal
of Pharmacological and Toxicological Methods, 2000, 44, 235YY249.
[48] Lipinski, C. Poor aqueous solubility Van industry-wide problem in drug discovery. American
Pharmaceutical Review, 2002, 5, 82YY85.
[49] Pharma Algorithms, Toronto, Canada. Algorithm Builder V1.8 and ADME Boxes V2.5 computer
programs (http://www.apalgorithms.com; date accessed 7 September 2006).
[50] Advanced Chemistry Development Inc., Toronto, Canada. ACD/Solubility DB computer program
(http://www.acdlabs.com; date accessed 16 January 2006).
[51] Maylan, W. M., & Howard, P. H. Estimating log P with atom/ fragments and water solubility with log
P. Perspect. Drug Design and Discovery, 2000, 19, 67YY84.
[52] Glomme, A., März, J., & Dressman, J. B. Comparison of a miniaturized shake-flask solubility method
with automated potentiometric acid/base titrations and calculated solubilities. Journal of
Pharmaceutical Sciences, 2005, 94, 1YY16.
[53] Faller, B., & Wohnsland, F. Physicochemical parameters as tools in drug discovery and lead
optimization. In: Testa, B., van de Waterbeemd, H., Folkers, G., & Guy, R. (eds) Pharmacokinetic
Optimization in Drug Research. 2001, (pp. 257YY274). Verlag Helvetica Chimica Acta, Zü rich and
WileyVVCH: Weinheim.
[54] Bergströ M, C. A. S., Luthman, K., & Artursson, P. Accuracy of calculated pH-dependent aqueous
drug solubility. European Journal of Pharmaceutical Sciences, 2004, 22, 387YY398.
[55] Bakatselou, V., Oppenheim, R. C., & Dressman, J. B. Solubilization and wetting effects of bile salts in
the dissolution of steroids. Pharmaceutical Research, 1991, 8, 1461YY1469.
[56] Higuchi, T., Shih, F.-M., Kimura, T., & Rytting, J. H. Solubility determination of barely aqueous-soluble
organic solids. Journal of Pharmaceutical Sciences, 1979, 68, 1267YY1272.
[57] Streng, W. H., Yu, D. H.-S., & Zhu, C. Determination of solution aggregation using solubility,
conductivity, calorimetry, and pH measurement. International Journal of Pharmaceutics, 1996, 135,
43YY52.
[58] Zhu, C., & Streng, W. H. Investigation of drug self-association in aqueous solution using calorimetry,
conductivity, and osmometry. International Journal of Pharmaceutics, 1996, 130, 159YY168.
[59] Smith, S. W., & Anderson, B. D. Salt and mesophase formation in aqueous suspensions of lauric
acid. Pharmaceutical Research, 1993, 10, 1533YY1543.
[60] Fini, A., Fazio, G., & Feroci, G. Solubility and solubilization properties of non-steroidal
antiinflammatory drugs. International Journal of Pharmaceutics, 1995, 126, 95YY102.
[61] Bouligand, Y., Boury, F., Devoisselle, J.-M., Fortune, R., Gautier, J.-C., Girard, D., Maillol, H., & Proust,
J.-E. Ligand crystals and colloids in water YYamiodarone systems. Langmuir, 1998, 14, 542YY546.
[62] Roseman, T. J., & Yalkowsky, S. H. Physicochemical properties of prostaglandin F2ò (tromethamine
salt): Solubility behavior, surface properties, and ionization constants. Journal of Pharmaceutical
Sciences, 1973, 62, 1680YY1685.
266 Aditya Sharma et al.
https://t.me/med1917
[63] Jinno, J., Oh, D.-M., Crison, J. R., & Amidon, G. L. Dissolution of ionizable water-insoluble drugs: The
combined effect of pH and surfactant. Journal of Pharmaceutical Sciences, 2000, 89, 268YY274.
[64] Avdeef, A., Voloboy, D., & Foreman, A. Dissolution YY Solubility: PH, buffer, salt, dual-solid, and
aggregation effects. In: Testa, B. & van de Waterbeemd, H. (eds) Comprehensive Medicinal
Chemistry II, Vol. 5 ADME-TOX Approaches. 2006, Elsevier: Oxford, UK, in press.
[65] Avdeef, A. High-throughput measurements of solubility profiles. In: Testa, B., Van de Waterbeemd,
H., Folkers, G., & Guy, R. (eds) Pharmacokinetic Optimization in Drug Research. 2001,
(pp. 305YY326). Verlag Helvetica Chimica Acta: Zü rich and Wiley: Weinheim.
[66] Avdeef, A. Physicochemical Profiling (Permeability, Solubility, Charge State). Current Topics in
Medicinal Chemistry, 2001, 1, 277YY351.
[67] Avdeef, A., & Testa, B. Physicochemical profiling in drug research: A brief state-of-the-art of
experimental techniques. Cellular and Molecular Life Sciences, 2003, 59, 1681YY1689.
[68] Okimoto, K., Rajewski, R. A., Uekama, K., Jona, J. A., & Stella, V. J. The interaction of charged and
uncharged drugs with neutral (HP-b-CD) and anionically charged (SBE7-b-CD) bcyclodextrins.
Pharmaceutical Research, 1996, 13, 256YY264.
[69] Wen, X., Liu, Z., Zhu, T., Zhu, M., Jiang, K., & Huang, Q. Evidence for the 2:1 molecular recognition
and inclusion behavior between b- and g-cyclodextrins and cinchonine. Bioorganic Chemistry, 2004,
32, 223YY233.
[70] Liu, H., Sabus, C., Carter, G. T., Du, C., Avdeef, A., & Tischler, M. In vitro permeability of poorly
aqueous soluble compounds using different solubilizers in the PAMPA assay with liquid
chromatography/mass spectrometry detection. Pharmaceutical Research, 2003, 20, 1820YY1826.
[71] Chen, H., Zhang, Z., McNulty, C., Cameron, O., Yoon, H. J., Lee, J. W., Kim, S. C., Seo, M. H., Oh, H. S.,
Lemmo, A. V., Ellis, S. J., & Heimlich, K. A high-throughput combinatorial approach for the discovery
of a Cremophor EL-free paclitaxel formulation. Pharmaceutical Research, 2003, 20, 1302YY1308.
[72] Bendels, S., Tsinman, O., Wagner, B., Lipp, D., Parrilla, I., Kansy, M., & Avdeef, A. Pampa-excipient
classification Gradient maps. Pharmaceutical Research, 2006, 23, 2525YY2535.
[73] Beckman Coulter, Inc., Fullerton, CA, USA. Biomek\ FX Automated Assay Optimization (http://www.
beckman.com; date accessed 16 January 2006).
[74] Taylor, P. Optimising assays for automated platforms. Modern Drug Discovery, 2002, December
issue, 37YY39.
[75] Tye, H. Application of statistical F design of experiments_ methods in drug discovery. Drug
Discovery Today, 2004, 9, 485YY491.
[76] Uch, A. S., Hesse, U., & Dressman, J. B. Use of 1-methylpyrrolidone as a solubilizing agent for
determining the uptake of poorly soluble drugs. Pharmaceutical Research, 1999, 16, 968YY971.
[77] Rytting, E., Lentz, K. A., Chen, X.-Q., Qian, F., & Venkatesh, S. Aqueous and cosolvent solubility data
for drug-like organic compounds. The AAPS Journal, 7, E78YYE105 2005. (http://www.aapsj.org; date
accessed 7 December 2005).
[78] Dressman, J. B. Dissolution testing of immediate-release products and its application to forecasting
in vivo performance. In: Dressman, J. B. & Lennernäs, H. (eds) Oral Drug Absorption. 2000,
(pp. 155YY181). Dekker: New York.
[79] Avdeef, A., & Bucher, J. J. Accurate measurements of the concentration of hydrogen ions with a glass
electrode: Calibrations using the Prideaux and other universal buffer solutions and a computer-
controlled automatic titrator. Analytical Chemistry, 50, 2137YY2142.
11 Applications and molecular simulation strategies 267
https://t.me/med1917
https://t.me/med1917
Abhishek Singh, Seema Yadav, Narahari Narayan Palei
✶
,
and Biswa Mohan Sahoo
12 Application of simulation system for
selection of nanocarrier for
biopharmaceutically challenging
pharmaceuticals
Abstract: Biopharmaceutically challenging pharmace uticals, characterized by their
large molecular size, hydrophobic nature, and susceptibility to degradation, present a
paradigm shift in the therapeutic landscape. Simulation tools play a major role in the
nanocarrier selection process for drugs that require biopharmaceutical. By simulating
the behavior of different nanocarriers under varying physiological conditions, re-
searchers may anticipate how different nanocarriers interact with potentially chal-
lenging drugs. It can predict both the controlled release of drug molecules and the
efficiency of the drug-loading process on a nanocarrier. Using this knowledge is neces-
sary to design drug delivery systems that minimize systemic side effects and maxi-
mize drug concentration at the target site. This chapter has discussed computational
techniques, simulation systems, and molecular dynamic simulations. It illustrates
how, as biological complexity and computing power combine to open up new possibil-
ities for the creation of safer, more effective, and tailored therapeutic interventions,
simulation will be essential in shaping the future of nanomedicine. In summary, sim-
ulation syste ms are an invaluable resource for rational drug design. This allows to
choose the right nanocarriers for biopharmaceutically complicated drugs, which in
turn helps them develop safer, more efficient drug delivery systems.
Keywords: Simulation, Nanocarriers, Molecular dynamic, Computational techniques
12.1 Introduction
In the rapidly evolving landscape of pharmaceutical sciences, the precise delivery of
therapeutic agents, especially biopharmaceutically challenging p harmaceuticals, is
a paramount challenge [1]. The distinct physicochemical characteristics of these sub-
✶
Corresponding author: Narahari Narayan Palei, Amity Institute of Pharmacy, Amity University,
Lucknow Campus, Lucknow 226010, Uttar Pradesh, India
Abhishek Singh, Seema Yadav, Amity Institute of Pharmacy, Amity University, Lucknow Campus,
Lucknow 226010, Uttar Pradesh, India
Biswa Mohan Sahoo, School of Pharmacy and Life Sciences, Centurion University of Technology &
Management, Bhubaneswar, Khurda-752050, Odisha, India
https://doi.org/10.1515/9783111208671-012
https://t.me/med1917
stances call for creative approaches to ensure their effectiveness while avoiding in-
herent drawbacks in traditional drug delivery techniques. One of the cutting-edge
approaches is the use of simulation systems, which have become a key tool in the delib-
erate design and selection of nano-carriers, a necessary step toward obtaining precision
in drug administration [2]. The development of nanotechnology has opened up a world
of possibilities in the complex field of medicines, especially in tackling the difficulties
posed by medications that pose biopharmaceutical challenges [3]. These compounds,
often revered for their therapeutic potential, present an array of hurdles when it comes
to effective drug delivery. The narrative of this chapter is woven around the profound
intersection of nanotechnology and pharmaceutical science, focusing on the application
of simulation systems for the judicious selection of nanocarriers, a critical stride toward
overcoming the challenges posed by these unique pharmaceutical entities [4].
Biopharmaceutically challenging pharmaceuticals, characterized by their large
molecular size, hydrophobic nature, and susceptibility to degradation, present a
paradigm shift in the therapeutic landscape [5]. Traditional drug delivery methods,
optimized for small molecules, encounter limitations in addressing the nuanced re-
quirements of these entities. As we delve into this intricate domain, the utilization
of nanocarrier surfaces as a promising avenue, offering the potential to surmount
the barriers in herent in the delivery of challenging pharmaceuticals [6]. Nanocar-
riers, ranging from liposomes to polymeric nanoparticles, embody a new frontier in
drug delivery. Engineered at the nanoscale, these carriers exhibit unique physico-
chemical properties that can be tailored to encapsulate and transport a diverse
array of therapeutic payloads. Their ability to navigate biological b arriers, modulate
drug-release kinetics, and provide targeted delivery positions them as agents of pre-
cision in the realm of pharmaceutical science [7].
The use of simulation systems is at the core of this revolutionary journey. These
computational approaches, such as molecular dynamic (MD) simulations, Monte Carlo
(MC) simulations, and quantitative structure–activity relationship (QSAR) modeling,
provide an unmatched understanding of the molecular complexities governing the in-
teractions between nanocarriers and pharmaceuticals that are biopharmaceutically
complex [8]. Simulation systems provide a virtual platform for researchers to explore,
analyze, and optimize the performance of nanocarriers, guiding the design process
with efficiency and accuracy [9].
This exploration into the application of simulation systems for the selection of
nanocarriers is not merely a scientific pursuit – it is a strategic endeavor to revolu-
tionize drug delivery [10]. As we navigate the chapters that follow, we embark on a
journey to unravel the theoretical underpinnings, computational methodologies, and
real-world applications of simulation systems. This endeavor is poised to contribute
significantly to the advancement of precision medicine, providing scientists and prac-
titioners with tools to navigate the intricate landscape of biopharmaceutically chal-
lenging pharmaceuticals with unparalleled finesse [11].
270 Abhishek Singh et al.
https://t.me/med1917
12.1.1 Significance of biopharmaceutically challenging
pharmaceuticals
Pharmaceuticals that are biopharmaceutically complex, including biologics, peptides, and
other big molecules, show great potential for treating diseases that had previously been
incurable. While giving significant therapeutic efficacy, their distinctive molecular proper-
ties also provide difficulties in formulation and delivery [12]. These difficult medications
must frequently be delivered in order for diseases, including cancer, autoimmune disor-
ders, and neurological illnesses, to be effectively treated. Therefore, it is crucial for devel-
oping modern medicine to understand and overcome the difficulties related with their
delivery [13]. According to recent studies, novel biopharmaceuticals are rapidly expanding
and have made new therapeutic options possible. Numerous researchers participate in
the improvement of biopharmaceuticals and produce exciting outcomes. From a scientific
and regulatory perspective, biopharmaceuticals show promise. Scientific issues, with the
expansion of biotechnologies, have led to an increased range of novel biopharmaceuticals
being marketed and employed for scientific software program applications globally.
These obstacles include regulatory issues as well.
Even if several scientific problems remain unresolved, biopharmaceuticals have been
significantly used for disorder control, prevention, and prognosis [14]. The Figure 12.1
demonstrates how traditional drugs can harm healthy tissues, emphasizing the impor-
tance of precise drug delivery. It also shows how nano- medicines target specific areas,
reducing unintended damage.
12.1.2 The conundrum of traditional drug delivery methods
Drug delivery techniques that have been used traditionally for years to administer
small-molecule medications are inadequate to meet the complex needs of pharmaceuti-
cals that provide a biopharmaceutical challenge [15]. Huge restrictions are imposed by
gastrointestinal barriers, enzymatic breakdown, and problems in absorption. The limits
that serve as a backdrop for the story drive the creation of efficient medication delivery
techniques, which are essential for maximizing therapeutic results while reducing side
effects in the field of medical science. Traditional medication delivery techniques, while
frequently effective, frequently pose a puzzle that scientists and researchers are slav-
ishly trying to solve. This riddle includes issues such restricted targeted distribution,
varying absorption rates, and the possibility of negative reactions. This essay examines
the subtleties of conventional drug delivery techniques, pointing out their drawbacks
and examining creative options that could usher in a new era of medicines – investiga-
tion of different tactics that go beyond the conventional paradigms [16].
12 Application of simulation system for selection of nanocarrier 271
https://t.me/med1917
12.1.2.1 The limitations of traditional drug delivery
The distribution of therapeutic substances to specific areas within the body has long
been a difficulty in the dynamic field of pharmaceuticals. Despite their foundational
nature, traditional medication delivery techniques have certain drawbacks. A more
complex picture of these limitations becomes clear when we examine them closely,
highlighting the necessity of innovation in medication delivery methods [17].
12.1.2.2 Poor bioavailability
Achieving adequate bioavailability is a challenge for conventional drug delivery, partic-
ularly for drugs with low solubility. This restriction results from the use of traditional
formulations, which might not fully address the physicochemical characteristics of
some medications. As a result, it becomes difficult to achieve therapeutic concentrations
at the target site, which results in less-than-ideal efficacy [18].
12.1.2.3 Short half-life
Many medications given by conventional means have a brief half-li fe in the blood.
Frequent dosing is required since the duration of the rapeutic activity is diminished
by rapid metabolism and elimination by the body. In addition to creating difficulties
for patient compliance, this frequent administration raises the possibility of systemic
toxicity [19].
12.1.2.4 Inefficient crossing of biological barriers
It can be difficult for some medications to effectively pass biological barriers, such the
blood–brain barrier. This restriction limits the use of conventional drug delivery tech-
niques in the treatment of illnesses when therapeutic medicines must enter the body
at particular anatomical sites.
12.1.2.5 Limited control over drug release
Therapeutic agent release is frequently not precisely controlled by conventional drug
delivery methods. Drug concentrations may peak and trough in immediate release
formulations, while timely therapeutic levels may be difficult to attain in prolonged
release formulations. The optimization of pharmacokinetics is hampered by this lack
of control [20].
272 Abhishek Singh et al.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана